Rare diseases
Investigational molecules
Locations
Recruiting trials first
2 clinical trials in this condition
France
BelgiumIn short
Hyperoxaluria is a condition where too much of a substance called oxalate builds up in your urine, potentially leading to kidney stones, kidney damage, and serious complications affecting other organs in your body. Managing this condition requires careful attention, specialized medical care, and—depending on the type—a combination of treatments designed to protect your kidneys and improve your quality of life.
When someone receives a diagnosis of hyperoxaluria, the primary goal of treatment is to reduce the amount of oxalate in the urine and prevent the formation of calcium oxalate crystals that can damage the kidneys. The approach to treatment depends heavily on which type of hyperoxaluria you have, how advanced the condition is, and how well your kidneys are functioning at the time of diagnosis.
There are three main types of hyperoxaluria: primary, enteric, and dietary. Primary hyperoxaluria is a rare inherited disorder caused by genetic changes that affect the liver's ability to regulate oxalate production. Enteric hyperoxaluria occurs when digestive system problems cause your body to absorb too much oxalate from food. Dietary hyperoxaluria results from eating too many high-oxalate foods. Each type requires a somewhat different treatment strategy, though many approaches can help across all types.
The treatment journey often begins with conservative measures—steps you can take at home and lifestyle changes—then progresses to more intensive interventions if kidney function declines. For people with primary hyperoxaluria, early diagnosis and aggressive treatment are especially critical because this form tends to be more severe and can lead to kidney failure, particularly in children. Approximately 50% of infants who develop primary hyperoxaluria will experience kidney failure by age 15, and about 80% by age 30.
Standard treatment for hyperoxaluria focuses on reducing oxalate levels in the urine, preventing kidney stones from forming, and protecting kidney function. The cornerstone of conservative treatment is hyperhydration, which means drinking large amounts of water throughout the day. This helps flush oxalate through your kidneys before it can combine with calcium to form stones or crystals.
The amount of water needed varies by age and body size. Adults and older adolescents typically need to drink about 4 liters (approximately 135 ounces or 17 cups) of water each day. School-age children need 2-3 liters (68-101 ounces or 8-13 cups) daily, while infants and small children require 1-1.5 liters (34-51 ounces or 4-6.5 cups). Some infants or people who struggle to drink enough may need a feeding tube (called a gastrostomy tube or G-tube) to ensure adequate fluid intake.
For some patients with primary hyperoxaluria type 1, pyridoxine (vitamin B6) can be helpful. This vitamin acts as a cofactor for certain liver enzymes and may reduce oxalate production in responsive patients. However, one study found that about two-thirds of patients with primary hyperoxaluria type 1 do not respond to pyridoxine therapy at all. Because of this, doctors typically recommend a trial period to see if it works; if no response is seen, the treatment is discontinued.
Crystallization inhibitors are medications that help prevent oxalate from combining with calcium to form stones. The most commonly used options include potassium citrate and oral phosphate supplements. Potassium citrate is generally used when kidney function (measured by glomerular filtration rate or GFR) is well preserved. For patients with lower GFR who are at risk of developing high potassium levels in their blood, sodium citrate may be used instead. These medications work by making the urine less favorable for crystal formation.
Dietary changes are recommended for all types of hyperoxaluria, though they are most important for dietary and enteric types. While people with primary hyperoxaluria overproduce oxalate in their liver regardless of diet, avoiding extremely high-oxalate foods can still prevent adding to the problem. Foods particularly high in oxalate include spinach, rhubarb, chocolate, cocoa, black tea, nuts, peanut butter, and star fruit. Patients should work with a registered dietitian to create a personalized eating plan that avoids unnecessary restrictions while limiting oxalate intake.
Calcium intake deserves special attention. While it might seem counterintuitive, eating adequate calcium can actually help by binding to oxalate in the digestive tract, preventing it from being absorbed into the bloodstream and eventually reaching the kidneys. The calcium-oxalate complex then leaves the body in stool rather than urine. However, patients should generally avoid vitamin C supplements, as vitamin C is converted to oxalate in the body and can worsen the condition.
When kidney stones do form despite preventive measures, they must be removed. The preferred surgical approach is percutaneous nephrolithotomy (PCNL), a procedure where stones are removed through a small incision in the back. For smaller stones or when PCNL is not suitable, ureteroscopy (using a thin scope inserted through the urinary tract) may be performed. Importantly, a common stone-removal technique called extracorporeal shock wave lithotripsy (ESWL) is not recommended for hyperoxaluria patients because the shock waves can cause additional kidney injury in these already vulnerable kidneys.
As kidney function declines, more intensive interventions become necessary. When the glomerular filtration rate drops below 30-45 ml/min, oxalate production by the liver begins to exceed what the kidneys can eliminate. This leads to oxalate building up in the blood and depositing in other tissues throughout the body, a life-threatening condition called systemic oxalosis. At this stage, patients typically require dialysis to help remove oxalate from the blood.
For hyperoxaluria patients with kidney failure, dialysis alone is often insufficient. Standard hemodialysis three times per week cannot remove enough oxalate to prevent systemic accumulation. Many patients need intensive dialysis regimens—sometimes six days per week—combined with peritoneal dialysis to maximize oxalate removal. Even with this aggressive approach, dialysis can eliminate less than half of the oxalate the liver produces each day. This makes dialysis a temporary solution rather than a long-term answer for most patients with primary hyperoxaluria.
For many patients with primary hyperoxaluria who develop advanced kidney disease, organ transplantation becomes necessary. Because the problem originates in the liver, a combined liver-kidney transplant is often recommended. The new liver corrects the metabolic defect that causes oxalate overproduction, while the new kidney provides normal filtering function. This is typically recommended when patients reach stage 3b chronic kidney disease. Studies show that 34% to 46% of patients with primary hyperoxaluria type 1 and 11% of patients with type 2 eventually require organ transplantation. However, transplantation comes with significant challenges: 23% to 36% of transplanted organs may fail within five years, and recipients must take immunosuppressant medications for life to prevent rejection.
Recent years have brought exciting developments in hyperoxaluria treatment, particularly for primary hyperoxaluria type 1. The most promising new therapies use a technology called RNA interference (RNAi), which works by silencing specific genes in the liver that are involved in oxalate production. This represents a fundamentally different approach—rather than trying to manage symptoms or compensate for excess oxalate, RNAi therapy addresses the root cause by reducing how much oxalate the liver makes in the first place.
Two RNAi therapies have been approved specifically for primary hyperoxaluria type 1. These medications work by targeting and breaking down the messenger RNA molecules that carry instructions for making certain liver enzymes. By reducing the production of lactate dehydrogenase in the liver—an enzyme that converts a substance called glyoxylate into oxalate—these therapies can significantly lower oxalate levels in both urine and blood.
The approval of RNAi therapies represents a major milestone because, until very recently, there was no medication specifically approved to treat any form of primary hyperoxaluria across all three known subtypes. While these new treatments currently target only type 1, research is ongoing to develop therapies for types 2 and 3 as well. Clinical trials have shown that patients treated with RNAi therapy experience meaningful reductions in urinary and plasma oxalate levels, which may slow or prevent kidney damage and reduce the burden of kidney stone disease.
Researchers are also exploring other innovative approaches. Gene therapy, which would involve correcting the genetic defect itself, is being investigated for primary hyperoxaluria. Enzyme replacement or augmentation strategies—providing patients with the missing or deficient enzyme—are another area of active research. Some studies are examining whether medications that inhibit specific metabolic pathways in the liver could reduce oxalate production through different mechanisms than RNAi.
For enteric hyperoxaluria, probiotics containing beneficial bacteria are being studied. One bacterium of particular interest is Oxalobacter formigenes, which naturally breaks down oxalate in the intestine. Research suggests that supplementing with this or similar bacteria might help the gut eliminate more oxalate before it can be absorbed into the bloodstream. While evidence is still preliminary, this approach could offer a simple, non-invasive option for reducing oxalate absorption in patients whose hyperoxaluria is related to digestive system problems.
Clinical trials for hyperoxaluria treatments typically progress through three phases. Phase I trials focus primarily on safety—determining what doses can be given without causing unacceptable side effects. Phase II trials evaluate whether the treatment actually works, measuring outcomes like reduction in urinary oxalate levels, fewer kidney stones, or improved kidney function. Phase III trials compare the new treatment against current standard care (or placebo) in larger groups of patients to confirm effectiveness and monitor for less common side effects.
Patients interested in clinical trials should discuss options with their healthcare team. Trials may be available through specialized centers in various locations including the United States, Europe, and other regions. The Rare Kidney Stone Consortium and patient advocacy organizations like the Oxalosis and Hyperoxaluria Foundation maintain registries and information about ongoing studies. Participating in a trial not only provides potential access to cutting-edge treatments but also contributes valuable data that advances understanding of these rare diseases.
This guide is here to help you understand the condition. It does not replace a conversation with your doctor, who knows your situation best.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
